Worldpharma Biotech will produce the first medical cannabis
products for clinical trials in Spain with Tilray GMP-certified
medical cannabis
Tilray medical cannabis will now be available in 17 countries
around the world
Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis
research, cultivation, production, and distribution, today
announced it has agreed with Worldpharma Biotech ("Worldpharma"),
through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda.
(“Tilray Portugal”), to export Good Manufacturing Processes (GMP)
certified medical cannabis from Portugal to Spain. The shipment
marks the first medical cannabis import into Spain by Worldpharma
and the 17th country to receive Tilray medical cannabis
worldwide.
The Agencia Española de Medicamentos y Productos Sanitorios
(AEMPS), Spain’s food and drug administration, has approved
Worldpharma to import Tilray’s GMP-certified medical cannabis as
raw material from its Portugal facility to Spain. With Tilray's
pharmaceutical-grade cannabis, Worldpharma will develop medical
cannabis products for clinical trials in Spanish Hospitals for
diseases such as Alzheimer's, Parkinson’s disease, and skin
inflammation.
Brendan Kennedy, Tilray’s Chief Executive Officer, said, “We’re
incredibly honored to be the first cannabis company to be approved
and to ship medical cannabis into Spain. As we continue to work
with regulators around the world, we are grateful to partner with
the AEMPS and established pharmaceutical leaders such as
Worldpharma Biotech on the distribution of Tilray medical
cannabis.”
Juan Jose Garcia Miquel, Founder of World Pharma Biotech, said,
"We are very happy to initiate a cannabis biomass supply agreement
with Tilray to supply our extraction and purification lab with
quality GMP certified products that meet the highest of E.U. and
Spanish Pharmacology Standards. We intend to work with the
companies with the highest quality pharmaceutical standards to give
doctors and patients total confidence. It's been impossible to
reach this level of quality from other cannabis authorized
companies in Spain.”
Sascha Mielcarek, Tilray’s General Manager for Europe, said, “We
are very pleased to partner with Worldpharma. Tilray is once again
establishing itself as a key player with solid expertise in the
service of patient well-being. Throughout its supply chain, Tilray
applies the highest medical standards that provide sustainable and
safe access to pharmaceutical-grade medical cannabis for patients
in need, paving the way for future medical cannabis standards of
care.”
Tilray has a pioneering track record as a company committed to
making GMP-certified, pharmaceutical-grade medical cannabis
products available to patients in need worldwide and was the first
to successfully export medical cannabis from North America and
import medical cannabis products into the E.U. in 2016.
Tilray's E.U. Campus in Portugal is a multi-faceted production
facility that includes research and quality control labs,
packaging, and distribution sites for medical cannabis. It also
serves as a hub supporting Tilray’s clinical research and product
development efforts across Europe. Tilray has established sales and
distribution arrangements to supply medical cannabis through major
pharmaceutical distribution channels throughout Germany and the
E.U., which will serve as a means to allowing patients to access
Tilray's GMP-certified finished medical cannabis.
About Tilray®
Tilray is a global pioneer in the research, cultivation,
production, and distribution of cannabis and cannabinoids,
currently serving tens of thousands of patients and consumers in 17
countries spanning five continents.
About WorldPharma Biotech
World Pharma Biotech was founded in 2014 in Valencia, Spain,
focused on vegetal ingredients for nutraceuticals, cosmetics, and
pharmaceutical industries. The company is located in the Scientific
Park of the University of Valencia, a center of Spin-off and
Start-up companies from Valencia University. The extraction and
purification lab's primary focus is the manufacturing of Active
Pharmaceutical Ingredients from Cannabis for the European
Pharmaceutical and Dermo Cosmetic Industry.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and "forward-looking information" within the meaning of
Canadian securities laws, or collectively, forward-looking
statements. Forward-looking statements in this press release may be
identified by the use of words such as, "may", "would", "could",
"will", "likely", "expect", "anticipate", "believe, "intend",
"plan", "forecast", "project", "estimate", "outlook" and other
similar expressions. Forward-looking statements are not a guarantee
of future performance and are based upon a number of estimates and
assumptions of management in light of management's experience and
perception of trends, current conditions, and expected
developments, as well as other factors that management believes to
be relevant and reasonable in the circumstances, including
assumptions in respect of current and future European market
conditions, the current and future regulatory environment and
future approvals and permits. Actual results, performance, or
achievement could differ materially from that expressed in, or
implied by, any forward-looking statements in this press release,
and, accordingly, you should not place undue reliance on any such
forward-looking statements, and they are not guarantees of future
results. Please see the heading "Risk Factors" in Tilray's
Quarterly Report on Form 10-Q, which was filed with the Securities
and Exchange Commission on November 9, 2020, for a discussion of
the material risk factors that could cause actual results to differ
materially from the forward-looking information. Tilray does not
undertake to update any forward-looking statements that are
included herein, except in accordance with applicable securities
laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210204005187/en/
For further information: Tilray Global: Berrin Noorata
news@tilray.com
To request an interview opportunity: Media Amy Bonwick
647-515-3748 amy@pomppr.com
Ranjit Dhatt 647-890-2445 ranjit@pomppr.com
Investors Raphael Gross 203-682-8253
Raphael.Gross@icrinc.com
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tilray Brands (NASDAQ:TLRY)
Historical Stock Chart
From Sep 2023 to Sep 2024